

December 12, 2007
Shionogi & Co., Ltd.

Shionogi Files Patent Infringement Actions in Response to Crestor[®] ANDAs in the USA

December 12, 2007 – Shionogi & Co., Ltd. (Head office: Osaka: President: Motozo Shiono) announced today that on December 11, 2007, for the patent Shionogi owns in the USA for Crestor[®], Shionogi and AstraZeneca have jointly filed patent infringement actions in United States District Court, District of Delaware, against seven generic drug manufacturers including Cobalt Pharmaceuticals, Inc. which have submitted Abbreviated New Drug Applications (ANDAs).

Crestor[®] (generic name: Rosuvastatin Calcium, treatment for hyperlipidemia) was discovered by Shionogi and out-licensed to AstraZeneca in the UK which developed and markets it all over the world. It is presently approved in more than 90 countries, and it is making a contribution to treating more than 11 million hyperlipemic patients.

Shionogi and AstraZeneca have full confidence in the validity of the patent and intend to vigorously enforce and defend it.

- (*)
- Cobalt Pharmaceuticals, Inc.
 - Apotex, Inc.
 - Mylan Pharmaceuticals Inc.
 - Sandoz Inc.
 - Aurobindo Pharma Ltd.
 - Par Pharmaceutical, Inc.
 - Sun Pharmaceutical Industries Ltd.

For further information, contact:

Public Relations Unit

Shionogi & Co., Ltd.

(Osaka)

TEL +81-6-6209-7885 FAX +81-6-6229-9596

(Tokyo)

TEL +81-3-3406-8164 FAX +81-3-3406-8099